The Ministry of Health, Labor and Welfare (MHLW) will issue its “blue book,” a systematic collection of the latest quality information on generic drugs compiled by active pharmaceutical ingredient (APIs), before the end of FY2016, which runs through next March.…
To read the full story
Related Article
- Blue Book “Will Be Used as Reference When Selecting Generics”: Panel Chair
September 14, 2016
REGULATORY
- MHLW Lifts Part of Approval Conditions for Takeda’s Vyvanse
June 9, 2026
- Drug Makers Seek Govt Support for Immunoglobulin Plant Investments: LDP Hearing
June 9, 2026
- Japan Govt Likely to Slim Down Honebuto, but Details Remain Elusive
June 8, 2026
- Leqembi, Kisunla Labels Revised to Strengthen ARIA Monitoring
June 8, 2026
- Japan Tightens Oversight of Mounjaro Resales: Health Minister
June 8, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





